In April 2020, the volunteer computing platform was restarted by the Ibercivis Foundation and the Spanish National Research Council in order to screen existing drugs for antiviral activity against Severe acute respiratory syndrome coronavirus 2, the causative agent of the COVID-19 pandemic.

[1] Ibercivis was developed in Spain with the cooperation of the Institute of Biocomputation and Physics of Complex Systems at the University of Zaragoza, CIEMAT, CETA-CIEMAT, the Spanish National Research Council (CSIC) and RedIris.

The larger-scale Ibercivis infrastructure has been used for a variety of calculating applications, including nuclear fusion research, protein folding and materials simulations.

In July 2009, the Ibercivis platform was extended to Portugal following an agreement signed by the governments of both countries during the Luso-Spanish Summit held in Zamora, Spain, in January 2009.

Several Portuguese institutions subsequently affiliated themselves with Ibercivis, including the Ministry of Science, the Centre for Neuroscience and Cell Biology at the University of Coimbra, and the LIP experimental high-energy physics laboratory.